Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    OpGen

    MCap

    USD15m

    Last close

    USD1.78

    ▲ 0.18 (11.13%)

    Substrate AI

    MCap

    EUR11m

    Last close

    EUR0.10

    ▲ 0.01 (11.11%)

    IRLAB Therapeutics

    MCap

    SEK679m

    Last close

    SEK13.10

    ▲ 1.00 (8.26%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

MagForce (DB: MF6)

Last close As at 29/10/2024

0.02

▲ 0.01 (100.00%)

Market capitalisation

—

Edison Investment Research is terminating coverage on MagForce. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

View More

Healthcare | QuickView

MagForce — Primed to execute on its growth strategy

Healthcare | Update

MagForce — Primed to execute on its growth strategy

Healthcare | Update

MagForce — Time to capitalise on growth potential

Healthcare | Update

MagForce — NanoTherm on track for US approval in 2021
Visit Website

Balance Sheet

Forecast net debt (€m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (73.9) (99.0) (99.5)
Relative (75.2) (99.0) (99.4)
52 week high/low €3.6/€0.0

Financials

MagForce is a German med-tech firm with a CE-mark approved nanotechnology cancer treatment. This consists of NanoTherm (iron nanoparticles), Nanoplan (software) and NanoActivator (a device that produces a powerful magnetic field to heat the nanoparticles, which destroys or sensitises tumour cells to therapy).

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2020A 0.6 19.3 (9.7) (0.35) N/A N/A
2021A 0.4 (6.1) (8.9) (0.30) N/A N/A
2022E N/A N/A N/A N/A N/A N/A
2023E N/A N/A N/A N/A N/A N/A

Research

Update

Healthcare

MagForce — Primed to execute on its growth strategy

Update

Healthcare

MagForce — Time to capitalise on growth potential

Healthcare

QuickView

MagForce — Primed to execute on its growth strategy

Update

Healthcare

MagForce — NanoTherm on track for US approval in 2021

Update

Healthcare

MagForce — Heading in the right direction

Update

Healthcare

MagForce — Winds of change

edison tv

Healthcare

MagForce – EKF interview

QuickView

Healthcare

MagForce — Striding towards major inflection points

Outlook

Healthcare

MagForce — Striding towards major inflection points

Update

Healthcare

MagForce — Key inflection points on the horizon

Update

Healthcare

MagForce — FDA approves streamlined trial protocol
View All

Thematics

View All

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free